In patients with advanced triple negative breast cancer, the combination of a CSF-1 monoclonal antibody with gemcitabine and carboplatin showed comparable anti-tumor activity and progression-free survival compared to gemcitabine and carboplatin alone [65]. The gene discussed is CSF1; the disease is triple-negative breast carcinoma.